Does Rallies show Form 4 insider transactions for TERN?

Yes. Rallies tracks TERN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TERN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TERN. It does not provide personalized investment advice.

TERN (Terns Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Terns Pharmaceuticals, Inc. Common Stock (TERN) is a publicly traded Healthcare sector company. As of May 20, 2026, TERN trades at $52.95 with a market cap of $6.12B and a P/E ratio of -51.41. TERN moved +0.07% today. Year to date, TERN is +23.37%; over the trailing twelve months it is +1412.86%. Its 52-week range spans $1.87 to $53.19. Analyst consensus is neutral with an average price target of $52.97. Rallies surfaces TERN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TERN stock inside the company?

Recent TERN insider activity includes Kuriakose Emil sold 942, Burroughs Amy L. sold 11.81K, Burroughs Amy L. sold 2.77K, Burroughs Amy L. sold 2.34K, and Burroughs Amy L. sold 8.16K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TERN Key Metrics

Key financial metrics for TERN
Metric	Value
Price	$52.95
Market Cap	$6.12B
P/E Ratio	-51.41
EPS	$-1.03
Dividend Yield	0.00%
52-Week High	$53.19
52-Week Low	$1.87
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-96.21M
Gross Margin	0.00%

Recent TERN Insider Trades

Kuriakose Emil sold 942 (~$49.69K) on Apr 1, 2026.
Burroughs Amy L. sold 11.81K (~$550.08K) on Mar 16, 2026.
Burroughs Amy L. sold 2.77K (~$131.03K) on Mar 16, 2026.
Burroughs Amy L. sold 2.34K (~$89.11K) on Feb 17, 2026.
Burroughs Amy L. sold 8.16K (~$319.96K) on Feb 17, 2026.

Latest TERN News

Merck Completes Terns Acquisition at $53 Per Share, Gains CML Breakthrough — May 6, 2026
Terns Secures FDA Breakthrough Designation for TERN-701, Merck Deal to Accelerate Trials — Apr 27, 2026
Terns Pharmaceuticals $53 Cash Sale to Merck Faces Fiduciary Probe — Apr 9, 2026
Merck to Acquire Terns for $6.7bn, Highlighting TERN-701’s 75% MMR in CML — Mar 30, 2026
Terns Pharmaceuticals’ $53 Cash Sale to Merck Faces Legal Scrutiny — Mar 26, 2026

TERN Analyst Consensus

6 analysts cover TERN: 0 strong buy, 0 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $52.97.

Common questions about TERN

Who is trading TERN stock inside the company?: Recent TERN insider activity includes Kuriakose Emil sold 942, Burroughs Amy L. sold 11.81K, Burroughs Amy L. sold 2.77K, Burroughs Amy L. sold 2.34K, and Burroughs Amy L. sold 8.16K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TERN?: Yes. Rallies tracks TERN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TERN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TERN. It does not provide personalized investment advice.